{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:21:09Z","timestamp":1789608069527,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014862","name":"YangZhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Although infliximab (IFX) is endorsed for induction therapy in severe ulcerative colitis (SUC), its therapeutic response remains heterogeneous. We conducted a comprehensive analysis of fecal and mucosal microbiota, coupled with targeted metabolomics, to delineate microbial and metabolic signatures predictive of IFX induction efficacy and to explore mechanistic pathways underlying differential treatment responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a prospective cohort study (clinical study registration number: ChiCTR2300071816). It enrolled adult patients aged \u2265 18 years who were first diagnosed with SUC at the First Affiliated Hospital of Nanjing Medical University and Northern Jiangsu People\u2019s Hospital between February 2022 and December 2023. None of these patients had received any medication for UC, including antibiotics. Clinical data, fecal samples, and rectal mucosal samples were collected for analysis. High-throughput sequencing of the 16S rRNA gene and non-targeted metabolomics analysis were performed on both fecal and rectal mucosal samples. All patients underwent IFX (5 mg\/kg) induced remission therapy at weeks 0, 2, and 6. Based on their clinical response at week 14, they were categorized into two groups: response and unresponse. Significant differences in bacterial composition between the two groups were identified by screening fecal and mucosal samples. The gut microbiota of feces and intestinal mucosa were combined with clinical data to create four prediction models and conduct comparisons. Furthermore, different metabolites from fecal and mucosal samples of the two groups were screened and compared with KEGG and PubChem databases to identify metabolic pathways associated with the efficacy of IFX-induced therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with non-responders, IFX responders harbor distinct gut microbiota. Clinical indices alone poorly forecast induction response (AUC 0.6429). Augmenting clinical variables with fecal or mucosal microbiota improves prediction to AUC 0.795 and 0.900, respectively; combining both compartments further elevates performance to AUC 0.964, indicating that integrated microbiome profiling is essential for optimal IFX response prediction. IFX responders and non-responders differ metabolically, with more discriminatory features in mucosa than feces. The most enriched differential pathways in feces included nicotinate and nicotinamide metabolism, butyrate metabolism, biosynthesis of valine, leucine, and isoleucine, pantothenate and coenzyme A biosynthesis, histidine metabolism, and alanine, aspartate, and glutamate metabolism. In mucosa, the most enriched differential pathways included alanine, aspartate, and glutamate metabolism, sphingolipid metabolism, ascorbate and aldarate metabolism, tryptophan metabolism, and D-glutamine and D-glutamate metabolism. The common pathway enriched in both feces and mucosa was alanine, aspartate, and glutamate metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The intestinal microbiota may be a predictive factor for IFX induction outcome in patients with SUC. The metabolic pathway of alanine, aspartate, and glutamate may be associated with the 14-week clinical response to IFX treatment in SUC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1779143","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:44:08Z","timestamp":1779342248000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The outcome of Infliximab induction in patients with severe ulcerative colitis may be related to intestinal microbiota"],"prefix":"10.3389","volume":"17","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Affiliated Subei People\u2019s Hospital of Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Cao","sequence":"additional","affiliation":[{"name":"The Affiliated Subei People\u2019s Hospital of Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoulu","family":"Jin","sequence":"additional","affiliation":[{"name":"The Affiliated Subei People\u2019s Hospital of Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Northern Jiangsu People\u2019s Hospital","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3748\/wjg.v21.i40.11469","article-title":"Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases.","volume":"157","author":"Aden","year":"2019","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.3748\/wjg.v21.i40.11469","article-title":"Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?","volume":"21","author":"Boon","year":"2015","journal-title":"World J. Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.18632\/aging.206250","article-title":"The aspartate superpathway in gut microbiota-related metabolic pathways mediates immune cell protection against COPD and IPF: a Mendelian randomization analysis.","volume":"17","author":"Chen","year":"","journal-title":"Aging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1756284820981210","DOI":"10.1177\/1756284820981210","article-title":"The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis.","volume":"13","author":"Chen","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ueg2.12720","article-title":"Multi-omics biomarkers for predicting efficacy of biologic and small-molecule therapies in adults with inflammatory bowel disease: a systematic review.","volume":"13","author":"Chen","year":"","journal-title":"U. Eur. Gastroenterol. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"112961","DOI":"10.4291\/wjgp.v16.i4.112961","article-title":"Gut microbiota as a potential predictor of therapeutic response in adults with Crohn\u2019s disease: a systematic review.","volume":"16","author":"Dutta","year":"2025","journal-title":"World J. Gastrointest Pathophysiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis.","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrgastro.2013.242","article-title":"Towards personalized care in IBD.","volume":"11","author":"Gerich","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1751-2980.12994","article-title":"Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing).","volume":"22","year":"2021","journal-title":"J. Digest. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e70093","DOI":"10.1002\/efd2.70093","article-title":"Gamma-Glutamyl-cysteine alleviates inflammatory bowel disease by suppressing the NF-\u03baB pathway in jejunum and modulating the gut microbiota.","volume":"25","author":"Jian","year":"2025","journal-title":"Eng. Life Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","article-title":"KEGG for taxonomy-based analysis of pathways and genomes.","volume":"51","author":"Kanehisa","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.","volume":"9","author":"Kopylov","year":"2016","journal-title":"Therapeut. Adv. Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"17562848241239580","DOI":"10.1177\/17562848241239580","article-title":"Systematic review of metabolomic alterations in ulcerative colitis: unveiling key metabolic signatures and pathways.","volume":"17","author":"Liu","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12964-025-02622-0","article-title":"Intestinal amino acid metabolic response and its roles in inflammatory bowel disease.","volume":"24","author":"Niu","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease monitoring in inflammatory bowel disease: evolving principles and possibilities.","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults.","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn\u2019s Disease in the United States.","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2036.2008.03878.x","article-title":"Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and na\u00efve patients.","volume":"29","author":"Swaminath","year":"2009","journal-title":"Aliment Pharmacol. Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.3390\/biomedicines11123144","article-title":"The role of the microbiome in the pathogenesis and treatment of ulcerative colitis-A literature review.","volume":"11","author":"\u015awirkosz","year":"2023","journal-title":"Biomedicines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","article-title":"Reliability and initial validation of the ulcerative colitis endoscopic index of severity.","volume":"145","author":"Travis","year":"2013","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ecco-jcc\/jjaa252","article-title":"Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease.","volume":"15","author":"Ventin-Holmberg","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0189424","DOI":"10.1128\/spectrum.01894-24","article-title":"The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab.","volume":"13","author":"Ventin-Holmberg","year":"2025","journal-title":"Microbiol. Spectr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2020.1865708","article-title":"Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn\u2019s disease.","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Microbes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.08.24311598","article-title":"A metabolic constraint in the kynurenine pathway drives mucosal inflammation in IBD.","author":"Welz","year":"2024","journal-title":"medRxiv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/ueg2.70064","article-title":"Gut microbial signatures associated with clinical remission in inflammatory bowel disease treated with biologics: a comprehensive multi-cohort analysis.","volume":"13","author":"Zheng","year":"2025","journal-title":"U. Eur. Gastroenterol. J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1284133","DOI":"10.3389\/fimmu.2023.1284133","article-title":"The role of amino acid metabolism in inflammatory bowel disease and other inflammatory diseases.","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e00188-17","DOI":"10.1128\/mSystems.00188-17","article-title":"Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction.","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1779143\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:44:09Z","timestamp":1779342249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1779143\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":29,"alternative-id":["10.3389\/fmicb.2026.1779143"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1779143","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1779143"}}